Unfortunately, the outcomes of several clinical trials involved the intrathecal infusion of recombinant BDNF to treat patients with amyotrophic lateral sclerosis have been disappointing due to the short in vivo half-life and poor delivery of BDNF [8, 9]. Here, BDNF is linked to amyotrophic lateral sclerosis.